How much cash does Regeneron Pharmaceuticals generate?

Regeneron Pharmaceuticals (REGN) generated $5.0B in operating cash flow over the trailing twelve months.

What is Regeneron Pharmaceuticals's free cash flow?

After $899.7M of capital expenditures, Regeneron Pharmaceuticals's free cash flow was $4.1B over the trailing twelve months, up 32.6% year over year.

Where does Regeneron Pharmaceuticals's cash flow data come from?

Every line is extracted from Regeneron Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

Regeneron Pharmaceuticals REGN Cash Flow Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY

Simplified Detailed

	FY'25	FY'24	FY'23	FY'22
Net income	$4.5B+2.1%	$4.41B+11.6%	$3.95B-8.9%	$4.34B-46.3%
Depreciation and amortization	$543.7M+12.6%	$482.9M+14.7%	$421M+23.3%	$341.4M+19.3%
Stock-based compensation	$993.7M+1.1%	$982.8M+11.1%	$885M+22.1%	$725M+20.5%
Change in accounts receivable	——	$554M+63.5%	$338.8M—	——
Change in inventories	$277.4M-55.2%	$619.7M+128%	$271.7M-61.0%	$696.5M+32.5%
Change in accounts payable	$761.5M+3.6%	$735.1M—	——	——
Change in deferred revenue	——	$249M+557%	$37.9M—	——
Net cash from operating activities	$4.98B+12.6%	$4.42B-3.8%	$4.59B-8.4%	$5.01B-29.2%
Capital expenditures	$898.4M+18.9%	$755.9M+5.2%	$718.6M+21.8%	$590.1M+6.9%
Net cash from investing activities	——	——	-$3.19B+19.9%	-$3.98B+27.8%
Dividends paid	$370.3M—	$0—	$0—	——
Repurchases of common stock	$3.44B+32.1%	$2.6B+16.5%	$2.24B+7.3%	$2.08B+26.6%
Proceeds from issuance of common stock	$635.9M-56.6%	$1.47B+27.9%	$1.15B-24.6%	$1.52B-9.1%
Taxes paid for net share settlement	$532.1M-48.3%	$1.03B+46.9%	$700.6M+57.2%	$445.7M-56.8%
Net cash from financing activities	-$3.72B-68.8%	-$2.2B-22.9%	-$1.79B-77.4%	-$1.01B—
Effect of exchange rate changes on cash	——	-$700K—	——	——
Net increase (decrease) in cash	$634.7M—	——	——	——
Interest paid	$41.6M-20.9%	$52.6M-28.0%	$73.1M+36.1%	$53.7M-3.8%
Increase (Decrease) in Deferred Income Taxes	$785.4M+3.7%	$757.3M-9.6%	$837.8M+12.2%	$746.4M+407%
Increase (Decrease) in Prepaid Expense and Other Assets	——	——	——	——
Other Noncash Income (Expense)	-$135.5M-275%	-$36.1M-36,200%	$100K+100%	-$368M+35.3%
Payments To Acquire Intangible Assets1	$315.3M+151%	$125.7M-39.5%	$207.8M-79.8%	$1.03B—
Other, net	——	-$33.4M—	——	$0—
Free cash flow	$4.08B+11.3%	$3.66B-5.4%	$3.88B-12.4%	$4.42B-32.2%
Free cash flow	$4.08B+11.3%	$3.66B-5.4%	$3.88B-12.4%	$4.42B-32.2%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Ask your AI about Regeneron Pharmaceuticals.

Connect your AI assistant and get a quick read on the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

How much cash does Regeneron Pharmaceuticals generate?: Regeneron Pharmaceuticals (REGN) generated $5.0B in operating cash flow over the trailing twelve months.
What is Regeneron Pharmaceuticals's free cash flow?: After $899.7M of capital expenditures, Regeneron Pharmaceuticals's free cash flow was $4.1B over the trailing twelve months, up 32.6% year over year.
Where does Regeneron Pharmaceuticals's cash flow data come from?: Every line is extracted from Regeneron Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.